Assay-kits

SensoLyte® 520 MMP-9 Assay Kit Fluorimetric - 1 kit

565.00
Check your price
  • Cat.Number : AS-71155
  • Availability :
    In stock
  • Shipping conditions : Ice delivery fees must be applied

Alternative choices

Quantity

MMP-9 (gelatinase-B, collagenase-IV) is involved in quite a few diseases such as a cancer, angiogenesis, alopecia and metastasis.
SensoLyte® 520 MMP-9 Assay Kit uses a 5-FAM (fluorophore) and QXL520™ (quencher) labeled FRET peptide substrates for continuous measurement of the enzyme activities. In an intact FRETpeptide, the fluorescence of 5-FAM is quenched by QXL520™. Upon the cleavage of the FRET peptide by MMP-9, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL520™ based FRET peptide is less interfered by the autofluorescence of test compounds and cellular components and provides better assay sensitivity.
Members of the MMP family have poor substrate sequence specificity, making it difficult to use a peptide substrate alone to differentiate the activity of a particular MMP from other MMPs. If several MMPs are coexisting in your samples and you would like to specifically measure MMP-9 activity, please choose the SensoLyte® Plus MMP-9 Assay Kit, Cat# AS-72017.

Specifications

Packaging
Kits components
  • Component A: MMP-9 substrate 5-FAM/QXL™520 FRET peptide Ex/Em=490 nm/520 nm upon cleavage: 60 µL Component B: 5-FAM-Pro-Leu-OH, Fluorescence reference standard Ex/Em=490 nm/520 nm: 1 mM, 10 µL Component C: APMA, 4-aminophenylmercuric acetate: 1 M, 20 µL Component D: Assay buffer: 20 mL Component E: Stop solution: 10 mL
Chemistry
UniProt number
  • P14780
Properties
Absorbance (nm)
  • 490
Emission (nm)
  • 520
Storage & stability
Storage Conditions
  • Store all components at -20°C. Protect Components A and B from light. Components D and E can be stored at 4°C for convenience.
Activity
Application
Biomarker Target
Detection Method
Detection Limit
  • 0.2 ng/ml
Research Area
Sub-category Research Area
Usage
  • Research use
Codes
Code Nacres
  • NA.32

You may also be interested in the following product(s)

Tube of ADAMTS-4 FRET substrate peptide

ADAMTS-4/Aggrecanase FRET Substrate, WAAG-3R - 1 mg

Cat.Number : AS-60431-1
293.00 Excl. Tax
Tube of Human MMP-9 (Catalytic Domain), Recombinant protein

MMP-9 (Catalytic Domain), human recombinant

Cat.Number : AS-55576-1
115.00 Excl. Tax

Citations

Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats

Cereb Cortex . 2011 Jun 17 ; 22(3) 725-34 | DOI : 10.1093/cercor/bhr158

  • M. Spolidoro
  • et al

Matrix metalloproteinase content and activity in low-platelet, low-leukocyte and high-platelet, high-leukocyte platelet rich plasma (PRP) and the biologic response to PRP by human ligament fibroblasts.

Am J Sports Med . 2014 Mar 13 ; 42 1211 | DOI : 10.1177/0363546514524710

  • M.A. Pifer
  • et al

Association of the MMP9 gene with childhood cedar pollen sensitization and pollinosis

J Hum Genet . 2012 Jan 12 ; 57 176 | DOI : 10.1038/jhg.2011.148

  • H. Inoue
  • et al

Urine matrix metalloproteinases (MMPs) as biomarkers for the progression of fracture healing.

Injury . 2012 Mar 01 ; 43 274 | DOI : 10.1016/j.injury.2011.05.038

  • N.A. Wigner
  • et al

Intracerebroventricular administration of an endothelin ETB-receptor agonist increases expression of matrix metalloproteinase-2 and -9 in rat brain

Neuroscience . 2007 Jun 06 ; 147 620 | DOI : 10.1016/j.neuroscience.2007.04.047

  • Y. Koyama
  • et al

A novel pharmacophore model for the design of anthrax lethal factor inhibitors

Chem Biol Drug Des . 2010 Jun 21 ; 76 263 | DOI : 10.1111/j.1747-0285.2010.01000.x

  • H. Yuan
  • et al

Rhodamine derivatives as selective protease inhibitors against bacterial toxins

Chem Biol Drug Des . 2008 Jan 19 ; 71 131 | DOI : 10.1111/j.1747-0285.2007.00617.x

  • S.L. Johnson
  • et al

Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein

Eur Respir J . 2008 Mar 05 ; 32 405 | DOI : 10.1183/09031936.00173207

  • O. Soehnlein
  • et al

A high-throughput screening approach to anthrax lethal factor inhibition

Bioorg Chem . 2007 Feb 22 ; 35 306 | DOI : 10.1016/j.bioorg.2006.12.005

  • S.L. Johnson
  • et al